Exscientia ends cancer study as it focuses on other trials of AI-driven drug candidates
03 Oct 2023
Clinical Study
AI drug discovery and development company Exscientia is stopping a solid tumor trial as it refocuses its internal pipeline amid plans to ink another partnership deal “by the end of this year,” CEO Andrew Hopkins told Endpoints News.
The Oxford, UK-based biotech will end a Phase Ib/IIa trial of its oral capsule EXS21546 in combination with Bristol Myers Squibb’s Opdivo, Exscientia said Tuesday morning. The company said it will explore potential partnerships for follow-up compounds it created for the A2A mechanism, noting “it will be challenging for ‘546 to reach a suitable therapeutic index.”
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.